论文部分内容阅读
目的评价恩替卡韦治疗慢性乙型肝炎的远期临床疗效及安全性.方法2006年1月至10月在门诊和住院的慢性乙型肝炎患者27例,其中 HBeAg阳性患者16例,HBeAg 阴性患者11例,均口服恩替卡韦片抗病毒治疗.结果治疗12周 ALT 复常率、HBV DNA 转阴率、e 抗原血清转换率分别为66.7%(18/27)、18.5%(5/27)、0,治疗24周分别为96.3%(26/27)、66.7%(18/27)、18.8%(3/16),治疗48周分别为100%(27/27)、96.3%(26/27)、31.3%(5/16),治疗72周分别为100%(27/27)、100%(27/27)、43.8%(7/16),治疗6年分别为100%(27/27)、100%(27/27)、56.3%(9/16).恩替卡韦治疗6年,所有患者均未出现明显临床不良反应.结论恩替卡韦能长期持续抑制病毒复制,疗效与安全性良好.“,”Objective To evaluate the long-term efficacy and safety of entecavir in the treatment of chronic hepatitis B. Metheds Twenty-seven chronic hepatitis B patients, including 16 HBeAg-positive patients and 11 HBeAg-negative patients, treated with entecavir monotherapy. Results The cumulative rates of ALT normalization, HBV-DNA undetectability, HBeAg seroconversion were 66.7% , 18.5% and 0, respectively, at 12 weeks; 96.3%, 66.7% and 18.8%, respectively, at 24 weeks; 100%, 96.3%, 31.3%, respectively, at 48 weeks; 100%, 100%, 43.8%, respectively, at 72 weeks; 100%, 100%, 56.3%, respectively, at 6 years. During the treatment period of six years, none drug-related adverse reactions were observed. Conclusions Entecavir is an effective and safe agent in long-term suppression activity against HBV for the treatment of CHB patients.